secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001564590-22-019851
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon Pharma Q1 net loss $9.9M; ALS topline data expected June 2022
--------------------------------------------------------------------

- Net loss $9.9M ($0.69/diluted share) vs $8.5M ($0.57) in Q1 2021.
- Cash $76.7M as of March 31, 2022, down from $84.8M; runway into 2024.
- Phase 2a ALS trial fully enrolled; topline data anticipated in June 2022.
- First patient dosed in Phase 2a IgA Nephropathy trial; initial data late 2022.
- Non-human primate study of tegoprubart monotherapy in kidney allograft rejection completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000156459022019851/0001564590-22-019851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000156459022019851/eldn-8k_20220512.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-019851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer